Phase 3 EXPAND trial suggests potential utility of siponimod
Novel monoclonal antibody takes aim at alpha-synuclein clusters
Most substantial reversal of amyloid deposition in an animal study to date
CSCs achieve timelier acute reperfusion therapy, national study finds
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
DEFUSE 3 results support lengthening treatment window in imaging-selected patients
One-year stroke mortality rate down by 18 percent over five years
First new medical intervention in a decade to demonstrate improved survival
Does the clinical benefit manifest electrophysiologically?
Advances toward biomarkers of progression are underway
Mounting evidence of PAP therapy’s benefits in largest series to date
Advertisement
Advertisement